Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Monica Neagu, Carolina Constantin & Cristiana Tanase. (2010) Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Review of Molecular Diagnostics 10:7, pages 897-919.
Read now
Read now
Blazej Zbytek, J Andrew Carlson, Jacqueline Granese, Jeffrey Ross, Martin Mihm & Andrzej Slominski. (2008) Current concepts of metastasis in melanoma. Expert Review of Dermatology 3:5, pages 569-585.
Read now
Read now
Articles from other publishers (23)
Katarzyna Kurpet & Grażyna Chwatko. (2022) S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases. Molecules 27:19, pages 6640.
Crossref
Crossref
Antonios Revythis, Sidrah Shah, Mikolaj Kutka, Michele Moschetta, Mehmet Akif Ozturk, George Pappas-Gogos, Evangelia Ioannidou, Matin Sheriff, Elie Rassy & Stergios Boussios. (2021) Unraveling the Wide Spectrum of Melanoma Biomarkers. Diagnostics 11:8, pages 1341.
Crossref
Crossref
Ahmad A. Tarhini, Sanjiv S. Agarwala, Arjun Khunger, Richard L. Wahl & Charles M. Balch. 2020. Cutaneous Melanoma. Cutaneous Melanoma
997
1043
.
Ahmad A. Tarhini, Sanjiv S. Agarwala, Arjun Khunger, Richard L. Wahl & Charles M. Balch. 2019. Cutaneous Melanoma. Cutaneous Melanoma
1
47
.
Chang Xia, Zachary Braunstein, Amelia C. Toomey, Jixin Zhong & Xiaoquan Rao. (2018) S100 Proteins As an Important Regulator of Macrophage Inflammation. Frontiers in Immunology 8.
Crossref
Crossref
Macanori Odashiro, Gunter Hans Filho, Patricia Rusa Pereira, Ana Rita Coimbra Motta Castro, Alcione Cavalheiro Stief, Elenir Rose Jardim Cury Pontes & Alexandre Nakao Odashiro. (2015) Melanoma inhibitory activity in Brazilian patients with cutaneous melanoma. Anais Brasileiros de Dermatologia 90:3, pages 327-332.
Crossref
Crossref
Gonzalo Blasco-Morente, María Sierra Girón-Prieto & Salvador Arias-Santiago. (2014) Técnicas serológicas útiles en oncología cutánea: biomarcadores. Piel 29:5, pages 300-308.
Crossref
Crossref
Debmalya Barh, Angelo Carpi, Mukesh Verma & Mehmet GunduzEijun Itakura & Alistair Cochran. 2014. Cancer Biomarkers. Cancer Biomarkers
911
928
.
Nadine Tandler, Birgit Mosch & Jens Pietzsch. (2012) Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids 43:6, pages 2203-2230.
Crossref
Crossref
Ahmad A. Tarhini & John M. Kirkwood. 2012. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma
305
317
.
Jochen Utikal, Jürgen C. Becker & Selma Ugurel. 2012. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma
9
18
.
Angel Díaz-Lagares, Estíbaliz Alegre, Ainhoa Arroyo, María González-Cao, Maria E. Zudaire, Santiago Viteri, Salvador Martín-Algarra & Alvaro González. (2011) Evaluation of multiple serum markers in advanced melanoma. Tumor Biology 32:6, pages 1155-1161.
Crossref
Crossref
L. Peuvrel, J.M. Nguyen, A. Khammari, G. Quereux, A. Brocard & B. Dreno. (2011) Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?. Journal of the European Academy of Dermatology and Venereology 25:11, pages 1311-1317.
Crossref
Crossref
Jagat R Kanwar, Neha Singh & Rupinder K Kanwar. (2011) Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine 6:4, pages 701-714.
Crossref
Crossref
Maja A. HOFMANN, Bernd SCHICKE, Andreas FRITSCH, Susanne BIESOLD, Felix GUSSMANN, Ingeborg KÜCHLER, Christiane VOIT & Uwe TREFZER. (2011) Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. The Journal of Dermatology, pages no-no.
Crossref
Crossref
Stanley P.L. Leong, Jeffrey E. Gershenwald, Seng-jaw Soong, Dirk Schadendorf, Ahmad A. Tarhini, Sanjiv Agarwala, Axel Hauschild, Christopher W.M. Soon, Adil Daud & Mohammed Kashani-Sabet. (2011) Cutaneous melanoma: A model to study cancer metastasis. Journal of Surgical Oncology 103:6, pages 538-549.
Crossref
Crossref
MAYS AL-SHAER, DIVYA GOLLAPUDI & CHRIS PAPAGEORGIO. (2010) Melanoma biomarkers: Vox clamantis in deserto (Review). Oncology Letters 1:3, pages 399-405.
Crossref
Crossref
Roger Mouawad, Jean-Philippe Spano & David Khayat. (2010) Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Research 20:2, pages 67-76.
Crossref
Crossref
H. Gogas, A.M.M. Eggermont, A. Hauschild, P. Hersey, P. Mohr, D. Schadendorf, A. Spatz & R. Dummer. (2009) Biomarkers in melanoma. Annals of Oncology 20, pages vi8-vi13.
Crossref
Crossref
Monica NeaguCarolina ConstantinGina MandaIrina Margaritescu. (2009) Biomarkers of metastatic melanoma. Biomarkers in Medicine 3:1, pages 71-89.
Crossref
Crossref
Ahmad A. Tarhini, Joseph Stuckert, Sandra Lee, Cindy Sander & John M. Kirkwood. (2009) Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694. Journal of Clinical Oncology 27:1, pages 38-44.
Crossref
Crossref
Simone Mocellin, Giorgio Zavagno & Donato Nitti. (2008) The prognostic value of serum S100B in patients with cutaneous melanoma: A meta‐analysis. International Journal of Cancer 123:10, pages 2370-2376.
Crossref
Crossref
Borki Vučetić, Sunčica Andreja Rogan, Pero Hrabač, Narcis Hudorović, Hrvoje Čupić, Ljerka Lukinac, Mario Ledinsky, Aljoša Matejčić, Ivo Lovričević & Mirta Zekan. (2008) Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Research 18:3, pages 201-207.
Crossref
Crossref